Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Effects of Silybum Marianum on Treatment of Patients With Chronic Hepatitis C

This study has been completed.
Information provided by:
Isfahan University of Medical Sciences Identifier:
First received: February 8, 2011
Last updated: NA
Last verified: September 2006
History: No changes posted
The purpose of this study is to determine the effects of silymarin on outcomes of patients with hepatitis C.

Condition Intervention Phase
Hepatitis C
Drug: Silymarin
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Study of Silymarin for Improving Hepatitis C

Resource links provided by NLM:

Further study details as provided by Isfahan University of Medical Sciences:

Primary Outcome Measures:
  • Serum aminotransferases (ALT, AST) [ Time Frame: at six months after admission ]
    The investigators measured serum amino transferases by commercial AST kit,. ALT kits(Bayer Diagnostics,. Tarrytown, NY, USA) at six months after silymarin admission

Secondary Outcome Measures:
  • HCV-RNA [ Time Frame: at six months after admission ]
    The investigators measured serum HCV-RNA by Polymerase Chain Reaction (PCR) at six months after silymarin admission

Enrollment: 55
Study Start Date: March 2006
Study Completion Date: September 2006
Primary Completion Date: September 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Silymarin drived from Silybum marianum (milk thistle), a flowering member of the daisy family, may benefit liver function in people infected with the hepatitis C virus.
Drug: Silymarin
Tab 210 mg, 630 mg, daily, six months.

Detailed Description:
Silymarin has been claimed to have a beneficial effect in various types of liver injury, including alcoholic liver disease, drug and toxin induced hepatotoxicity, and acute and chronic viral hepatitis.

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

confirmed chronic hepatitis C (HCV Ab (+), HCV RNA (with PCR) (+)) normal or increased liver enzymes (ALT and AST) not using interferon or ribavirin due to patient sensitivity or not consenting.

Exclusion Criteria:

The pregnant patients patients with side effect which confirmed with rechallenge test

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01292161

Iran, Islamic Republic of
Al-zahra university hospital
Isfahan, Iran, Islamic Republic of
Sponsors and Collaborators
Isfahan University of Medical Sciences
Principal Investigator: hamid kalantari, A.Professor Associate Professor,Gasteroentrology department
  More Information

Additional Information:
Responsible Party: Dr. Alireza Yousefy, Associate Professor of Medical Education, Isfahan University of Medical Sciences Identifier: NCT01292161     History of Changes
Other Study ID Numbers: ASD-1213-15
Study First Received: February 8, 2011
Last Updated: February 8, 2011

Keywords provided by Isfahan University of Medical Sciences:
Hepatitis C
Quality of life

Additional relevant MeSH terms:
Hepatitis A
Hepatitis C
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs processed this record on May 22, 2017